SNOA - Sonoma Pharmaceuticals, Inc.
| Previous Close | 1.50 |
| Open | 1.49 |
| Bid | 1.41 x 4000 |
| Ask | 1.69 x 1000 |
| Day's Range | 1.41 - 1.55 |
| 52 Week Range | 1.31 - 5.92 |
| Volume | 36,902 |
| Avg. Volume | 97,615 |
| Market Cap | 9.266M |
| Beta (3Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.85 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- GlobeNewswire•6 days ago
Sonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™
Sonoma Pharmaceuticals, Inc. (SNOA), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of a new Ceramax™ Skin Barrier Lotion. “We continue to receive positive physician and patient feedback on our current Ceramax cream, which we launched two years ago,” said Tom Devine, Sonoma Pharmaceutical’s dermatology division general manager. Both Ceramax products contain skin-enriching technology that helps manage dry itchy skin, minor skin irritations, rashes and inflammation caused by various skin conditions, including atopic dermatitis and allergic contact dermatitis.
- Simply Wall St.•11 days ago
Who Are The Major Shareholders In Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)?
A look at the shareholders of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...
- GlobeNewswire•27 days ago
Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L.
The Spanish/Portuguese formulation, to be branded as Ocudox™, will be marketed as a pre-surgical antimicrobial for use in eye surgery, intraoculus injections and any eye manipulation that requires sterile conditions. “We believe Spanish and Portuguese eye care professionals will find much to like about Ocudox with its rapid triple mode of action for treatment of eye conditions: Infection control, inflammation control and regeneration of healthy tissue around the eyes,” said Dr. Jordi Martínez Rotllan, director at Brill Pharma, S.L. “Yet, at the same time, the formulation is highly safe without side effects or any change to the patient’s DNA.
- GlobeNewswire•last month
Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
In 1999, Weigerstorfer joined Galencia Ltd’s executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market and with the acquisition of Canada-based Aspreva, in effectively forming Vifor Pharma Ltd in 2008. At Vifor he was responsible for the business development, licensing and M&A activities while based in Canada, and then based in Singapore, heading the regional operations in Asia Pacific as well as in the Middle East, the Commonwealth of Independent States, Africa, and Latin America.
- GlobeNewswire•2 months ago
Sonoma Pharmaceuticals Announces Results from Study of Sonoma’s Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris
Sonoma Pharmaceuticals, Inc. (SNOA), today announced that results from a study into the use of the company’s proprietary high-strength Performance-Stabilized HOClTM in the management of acne vulgaris were presented at the Practical Symposium Dermatology Conference in Colorado.
- GlobeNewswire•2 months ago
Sonoma Pharmaceuticals Reports First Quarter FY 2019 Financial Results
Total Revenue up 20% over March 2018 Quarter Total Revenue up 14% over June 2017 Quarter Conference Call Begins at 4:30pm EDT Today. PETALUMA, Calif., Aug. 08, 2018-- Sonoma Pharmaceuticals, Inc., today ...
- ACCESSWIRE•2 months ago
Sonoma Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 8, 2018 at 4:30:00 PM ...
- Simply Wall St.•4 months ago
Is Sonoma Pharmaceuticals Inc’s (NASDAQ:SNOA) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) with its market cap of US$16.23m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
- Benzinga•4 months ago
Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 13) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
- Simply Wall St.•5 months ago
Is Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) A Financially Sound Company?
Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) is a small-cap stock with a market capitalization of US$18.21M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
- ACCESSWIRE•6 months ago
Blog Exposure - FDA Granted New 510(k) Clearance to Sonoma Pharma’s Antimicrobial Post-Therapy Gel
LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Sonoma Pharma, Inc. (NASDAQ: SNOA ). If you want access to this report all you need to do is ...
- Benzinga•7 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Intercept Pharmaceuticals Inc (NASDAQ: ICPT ), a biopharmaceutical ...
- ACCESSWIRE•8 months ago
Dawson James Securities Announces Closing of $5 Million Public Offering for Sonoma Pharmaceuticals, Inc.
BOCA RATON, FL / ACCESSWIRE / March 7, 2018 / Dawson James Securities, Inc. in conjunction with Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, Warrants - SNOAW) today announced the March 6th closing of a ...
